Canopus Medical AB, the skin care development company, today announced that in support of customer requirements for increasing sales to key markets globally, it has successfully achieved certification by the International Organization for Standardization’s (ISO) highest Cosmetic standard – 22716 for Good Manufacturing Standards (GMP).
This certification of the production facility, granted on June 17, 2020, enables Canopus’s B2B and B2C cosmetics businesses to more readily access high potential markets, with innovative products, manufactured to the exacting quality and purity standards demanded for cosmetics.
Ali Ismail, CEO:
“Having received certification, we believe our addressable cosmetic growth opportunities are now significantly broadened, particularly in instances where ISO 22716 enables increased market access to new customers”.
ISO 22716 is an international standard that provides guidelines for the production, control, storage and distribution of cosmetic products. As a result, companies that have demonstrated GMP standards typically have a greater ability to pursue market penetration in markets where ISO certification provides a competitive advantage.
About Canopus Medical AB
Canopus Medical AB is a Swedish cooperation, which was founded by a senior dermatologist and a group of entrepreneurs, with the focus to provide the capacity to develop and produce batches of cosmeceutical products, for research and commercial purposes. Beside developing and commercializing its own label products, Canopus Medical also provides B2B opportunities to support the discovery, the development and the manufacturing of products for external customers.